Madrigal pharmaceuticals announces completion of enrollment in phase 3 maestro nafld-1 trial and reports 2020 third quarter financial results and highlights

Conshohocken, pa., nov. 05, 2020 (globe newswire) -- madrigal pharmaceuticals, inc. (nasdaq:mdgl) announced today that it completed enrollment in its maestro nafld-1 clinical trial of resmetirom in patients with presumed nash who are diagnosed using non-invasive assessments. the company also announced its third quarter 2020 financial results and highlights.
MDGL Ratings Summary
MDGL Quant Ranking